Corning Launches High-Throughput Label-Free Drug Screening System; New Corning(R) Epic(TM) system addresses a broad range of bio
18 Setembro 2006 - 9:30AM
Business Wire
Corning Incorporated (NYSE: GLW) today announced the commercial
launch of the Epic(TM) system, a high-throughput label-free
screening platform based on optical biosensor technology. The
system performs both biochemical and cell-based drug discovery
applications and offers drug developers the ability to evaluate
promising new drug targets. It also allows for the observation of
direct biological interactions not previously detectable in
high-throughput applications. The system uses optical technology to
eliminate the need for labels and consists of two basic components:
a disposable 384-well microplate with integrated biosensors and a
high-throughput screening (HTS) compatible microplate reader that
permits screening of up to 40,000 wells in an eight-hour period.
The Epic system can be easily integrated with existing facilities
and instrumentation because it makes use of an industry standard
microplate format. "Conventional drug screening technologies rely
heavily on the use of fluorescent or radioactive labels," said Mark
Beck, vice president and general manager, Corning Life Sciences.
"These labels can cause undesirable interactions such as false
positives or negatives, or prevent researchers from exploring
promising new drug targets because little information is known
about the target," continued Beck. "Prior to the introduction of
the Epic system, only very small-scale label-free experiments could
be performed, which did not address the needs of today's discovery
programs. Corning solved the difficult problem of enabling
label-free screening in high throughput by integrating our
expertise in optics, materials science and the life sciences to
bring this technology to market." The high sensitivity of the Epic
system makes it suitable for a broad range of drug discovery
applications, including both biochemical and cell-based assays.
Corning Life Sciences, in conjunction with multiple academic and
industry collaborators, has successfully evaluated numerous
small-molecule, large-molecule and cell-based interactions, and
several examples will be presented at the Society for Biomolecular
Sciences Conference in Seattle, Washington from September 17-21.
The Epic system will also be on display in the Corning exhibit
(booth #621). "The complexity associated with drug interactions
requires a broad understanding of the associated biology, and
researchers need to be able to evaluate this from many orthogonal
vantage points," commented Jeff Mooney, commercial technology
director, Corning Life Sciences. "The Epic system has the
sensitivity to detect small molecule binding interactions and to
measure endogenous level cellular response - all in the same
platform at high throughput," Mooney continued. "This means that
with a single instrument a researcher could screen, for example,
the binding between a small molecule drug and a kinase target, or
alternatively perform a cell-based GPCR screen using cells with
endogenously expressed receptors. There is no comparable system
commercially available today." For additional information on the
Epic system or any other Corning Life Sciences products, please
contact a customer service representative at 1-800-492-1110, toll
free in the United States, (+1) 978-635-2200 internationally, or
visit www.corning.com/lifesciences. About Corning Corning
Incorporated (www.corning.com) is a diversified technology company
that concentrates its efforts on high-impact growth opportunities.
Corning combines its expertise in specialty glass, ceramic
materials, polymers and the manipulation of the properties of
light, with strong process and manufacturing capabilities to
develop, engineer and commercialize significant innovative products
for the telecommunications, information display, environmental,
semiconductor, and life sciences industries. Forward-Looking and
Cautionary Statements This press release contains forward-looking
statements that involve a variety of business risks and other
uncertainties that could cause actual results to differ materially.
Forward-looking statements speak only as of the day that they are
made, and Corning undertakes no obligation to update them in light
of new information or future events.
Corning (NYSE:GLW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Corning (NYSE:GLW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024